Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Combination Products: US FDA Extends Safety-Reporting Deadline

Executive Summary

After major post-market safety reporting rule in 2016, guidance adds context for companies developing combination products. FDA also extends compliance deadlines in many cases until 2019.

You may also be interested in...



Combo-Product Sponsors Gain Some Favored Changes In Final Post-Market Reporting Rule

US FDA’s final rule includes several clarifications about its scope and definitions, and includes some additional reporting requirements.

Combo Product Sponsors Convince US FDA To Change Postmarket Reporting Rule

Final reg includes several clarifications about its scope and definitions, and also includes some additional reporting requirements.

Overflow Issue With Abbott COVID Tests Could Result In False Positives

The mixture in some faulty Abbott PCR tests could cause COVID-19 positive samples to flow into neighboring negative samples, resulting in false-positive results.

Topics

UsernamePublicRestriction

Register

PS122765

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel